Bedrijfsoverzicht
PharmaCyte Biotech, Inc. is a biotechnology entity dedicated to the development and commercial preparation of cellular therapies specifically designed to treat cancer through the utilization of live cell encapsulation technology within the United States. This approach relies on a proprietary cellulose-based platform known as Cell-in-a-Box, which serves as the foundation for their therapeutic candidates. The company operates within the broader Healthcare sector, specifically classified under the Biotechnology industry, a field characterized by high research and development expenditures and long cycles to market approval. Currently, the enterprise maintains a market capitalization of $7.01M and employs a workforce of 2 individuals, reflecting an extremely lean operational structure typical of early-stage clinical development firms. The combination of a market cap of $7.01M and the absence of reported annual revenue indicates that the firm is in a pre-revenue or pre-commercialization phase, where the primary focus is on advancing asset pipelines rather than generating immediate sales figures. This valuation scale suggests the company's equity value is derived almost exclusively from its intellectual property and potential future commercialization prospects rather than current financial performance or established market share.
Financiële gezondheid
The reported revenue for the trailing twelve months is listed as N/A, while the net income stands at a significant loss of $-7,486,426, and EBITDA is also recorded as N/A. The substantial negative net income relative to the non-existent revenue highlights a cost structure dominated by operational expenses, likely including research, development, and personnel costs, rather than cost of goods sold associated with product sales. The company's free cash flow is $-1,694,738, which signifies a continuous burn rate where cash outflows from operations and capital expenditures exceed any inflows, necessitating reliance on external financing or existing cash reserves to fund ongoing activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that mathematically results from the lack of revenue but reflects a company that has not yet achieved commercial scale to generate positive gross or operating leverage. On the balance sheet side, the company holds $20.54M in cash against $0 in debt, creating a conservative financial position that provides significant runway despite the lack of traditional equity ratios like debt-to-equity which is marked as N/A due to the absence of debt or equity data required for calculation. The current ratio is reported at 12.33, an exceptionally high liquidity metric that indicates the company possesses more than twelve times the current assets necessary to cover its short-term liabilities, suggesting a very low risk of insolvency in the immediate term. Return on Equity is -8.2% and Return on Assets is -6.8%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a common characteristic in the biotech sector during the clinical trial phases where asset generation precedes asset monetization.
Waarderingsbeoordeling
The P/E Ratio (TTM) is N/A because the company has not generated positive earnings, while the Forward P/E is listed as -1.72, a metric that is theoretically negative and indicates that analysts or data providers are projecting continued negative earnings or are using a specific calculation method that results in a negative multiple. The price-to-book ratio is 0.18, which indicates that the market values the company's equity at less than 20% of its book value, suggesting a deep discount relative to the accounting value of its assets. The price-to-sales ratio and EV/EBITDA are both listed as N/A, meaning traditional revenue-based or earnings-based valuation multiples cannot be applied given the lack of revenue and EBITDA data, forcing reliance on asset-based or market-cap-based valuation methods instead. The stock has traded between a 52-week low of $0.63 and a 52-week high of $1.51, and without the specific current share price in the provided facts, the absolute positioning cannot be calculated, though the range defines the recent volatility envelope. The beta value is 0.41, indicating that the stock's price volatility is significantly lower than the broader market, moving with only 41% of the intensity of the market index. This low beta suggests that the share price is less sensitive to general market fluctuations, which can be attributed to the company's small market cap and specialized biotechnology nature rather than broad economic cycles.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth rates versus revenue growth rates due to the absence of historical revenue data. Since the company does not pay a dividend, the dividend yield and payout ratio are both N/A and 0.0% respectively, which implies that the company retains all available cash to fund its operations and research initiatives rather than distributing income to shareholders. The 0.0% payout ratio confirms that the firm reinvests its limited financial resources entirely into growth objectives such as clinical trials and technology development, a standard strategy for biotechnology companies that have not yet reached profitability. Consequently, the overall growth and income profile is characterized by a complete absence of dividend income and reported revenue growth, focusing solely on capital appreciation potential derived from the successful advancement of its cellular therapy pipeline.